Your browser doesn't support javascript.
loading
An exploration of actigraphy in the context of ketamine and treatment-resistant depression.
Punturieri, Claire; Duncan, Wallace C; Greenstein, Dede; Shandler, Gavi; Zarate, Carlos A; Evans, Jennifer W.
Afiliação
  • Punturieri C; Experimental Therapeutics and Pathophysiology Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland, USA.
  • Duncan WC; Experimental Therapeutics and Pathophysiology Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland, USA.
  • Greenstein D; Experimental Therapeutics and Pathophysiology Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland, USA.
  • Shandler G; Experimental Therapeutics and Pathophysiology Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland, USA.
  • Zarate CA; Experimental Therapeutics and Pathophysiology Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland, USA.
  • Evans JW; Experimental Therapeutics and Pathophysiology Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland, USA.
Int J Methods Psychiatr Res ; : e1984, 2023 Sep 05.
Article em En | MEDLINE | ID: mdl-37668277
ABSTRACT

OBJECTIVES:

This study explored the potential of non-parametric and complexity analysis metrics to detect changes in activity post-ketamine and their association with depressive symptomatology.

METHODS:

Individuals with treatment-resistant depression (TRD n = 27, 16F, 35.9 ± 10.8 years) and healthy volunteers (HVs n = 9, 4F, 36.4 ± 9.59 years) had their activity monitored during an inpatient, double-blind, crossover study where they received an infusion of ketamine or saline placebo. All participants were 18-65 years old, medication-free, and had a MADRS score ≥20. Non-parametric metrics averaged over each study day, metrics derived from complexity analysis, and traditionally calculated non-parametric metrics averaged over two weeks were calculated from the actigraphy time series. A separate analysis was conducted for a subsample (n = 17) to assess the utility of these metrics in a hospital setting.

RESULTS:

In HVs, lower intradaily variability was observed within daily rest/activity patterns post-ketamine versus post-placebo (F = 5.16(1,15), p = 0.04). No other significant effects of drug or drug-by-time or correlations between depressive symptomatology and activity were detected.

CONCLUSIONS:

Weak associations between non-parametric variables and ketamine were found but were not consistent across actigraphy measures. CLINICAL TRIAL REGISTRATION ClinicalTrials.gov, NCT00088699.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Revista: Int J Methods Psychiatr Res Assunto da revista: PSIQUIATRIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Revista: Int J Methods Psychiatr Res Assunto da revista: PSIQUIATRIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos